Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
This study has been completed.
Study NCT00275431   Information provided by Ascenta Therapeutics

First Received on January 10, 2006.   Last Updated on June 24, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
More general conditions related to this trial
Interventions listed in this trial
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Sponsors listed in this trial